RESEARCH ARTICLE

The humoral immune response is essential for successful vaccine protection against paratuberculosis in sheep

Hannah B. Pooley *, Douglas J. Begg, Karren M. Plain, Richard J. Whittington, Auriol C. Purdie † and Kumudika de Silva †

Abstract

Background: The role played by the humoral immune response in animals vaccinated against a mycobacterial disease such as paratuberculosis, is not well understood. Sheep vaccinated against Mycobacterium avium subsp. paratuberculosis (MAP) can still become infected and in some cases succumb to clinical disease. The strength and location of the humoral immune response following vaccination could contribute to the ability of sheep to clear MAP infection. We examined the peripheral antibody response along with the localised humoral response at the site of paratuberculosis infection, the ileum, to better understand how this contributes to MAP infection of sheep following vaccination and exposure.

Results: Through assessing MAP specific serum IgG1 and IgG levels we show that the timing and strength of the humoral immune response directly relates to prevention of infection following vaccination. Vaccinated sheep that subsequently became infected had significantly reduced levels of MAP specific serum IgG1 early after vaccination. In contrast, vaccinated sheep that did not subsequently become infected had significantly elevated MAP specific serum IgG1 following vaccination. Furthermore, at 12 months post MAP exposure, vaccinated and subsequently uninfected sheep had downregulated expression of genes related to the humoral response in contrast to vaccinated infected sheep where expression levels were upregulated.

Conclusions: The timing and strength of the humoral immune response following vaccination against paratuberculosis in sheep directly relates to subsequent infection status. An initial strong IgG1 response following vaccination was crucial to prevent infection. Additionally, vaccinated uninfected sheep were able to modulate that response following apparent MAP clearance, unlike vaccinated infected animals where there was apparent dysregulation of the humoral response, which is associated with progression to clinical disease.

Keywords: Antibody, Paratuberculosis, Vaccination, Sheep, Humoral immunity, Ileum, ELISA, Gene expression, Infection

Background

Humoral immunity is believed to play a role in the protective response against intracellular mycobacterial pathogens, such as Mycobacterium avium subsp. paratuberculosis (MAP), the causative agent of paratuberculosis in ruminants [1, 2]. The pathogenesis of paratuberculosis was traditionally characterised by an increase in the humoral response measured through antibody production at the end stages of disease [3, 4]. The switch from an initial dominant cell mediated immune (CMI) response to a humoral response is often thought to signify a breakdown of disease control by the host and progression to clinical disease [5]. While it is undisputed that Interferon gamma (IFNγ) production is essential for overcoming mycobacterial infection [6], the pattern of a protective immune response to MAP infection is actually not so clear [7], with some studies showing MAP-specific antibody responses in sheep as early as...
two weeks post exposure (wpe) [8] and occurring at the same time as an IFNγ response [9].

The protection provided by vaccines against mycobacterial pathogens, particularly MAP, is often incomplete [10–12]. Sheep and cattle vaccinated against MAP have reduced incidence of clinical disease and faecal shedding, however commercial vaccines fail to prevent infection in all animals [13–15]. Understanding the mechanisms behind how some vaccinated animals successfully clear infection when others do not, would allow development of new vaccines to specifically target a protective immune response in all animals. Traditional markers to assess vaccine efficacy such as IFNγ and total antibody response in isolation are not able to differentiate between animals protected by vaccination and those that are not [16]. Therefore, there is a need to explore alternate or additional markers of vaccine protection to truly understand a protective vaccine response. To this point, most work on correlates of vaccine-induced protection against paratuberculosis has focused on the CMI response, however recent studies have suggested a role for B cells as well [16, 17].

B cells are pivotal in the activation and modulation of both CMI and humoral immune responses [18, 19]. B cells function as antigen presenting cells but also produce antibodies enabling immune complexes that can regulate the function of effector cells such as macrophages [17, 20–23]. In ruminants, the proliferative capacity of peripheral B cells is reduced in animals where vaccination fails to provide protection against MAP [16]. This response was noted as early as 13 weeks’ post MAP exposure. Additionally, a study by Begg and Griffin [24], found significantly higher percentages of B cells in the gut of vaccinated animals that survived MAP challenge compared to diseased animals. Therefore, although peripheral B cells may be functionally impaired, the humoral response at the site of infection might be more important to vaccine-induced protection.

The activity and survival of B cells at the site of infection has been examined in relation to disease progression for mycobacterial infections, but not in response to vaccination. B cells in the tissue can be activated by several different mechanisms, including direct antigen contact, ligation of the CD40 receptor by T cells and binding of B cell activating factor (BAFF) [17]. CD40 ligand (CD40L) deficiency predisposes humans to opportunistic infections by intracellular bacteria [25] and can be correlated with severe tuberculosis in macaques [26]. In contrast, the expression of BAFF by circulating populations of CD4+ T cells is associated with active tuberculosis [27]. Other indicators of the humoral immune response, including B cell surface markers (CD81), cytokines that promote B cell survival (MIFF) and transcription factors (JUN), have all been implicated in the progression or prevention of mycobacterial infections [28–30]. These apparent contradictions suggest that detailed examination of B cell functionality and the humoral response at the site of infection is required. Furthermore, the ability to understand whether the humoral response does provide vaccine-elicited protection against MAP requires an understanding of the host's ability to successfully mount this response at the site of infection.

We hypothesise that differences in B cell functionality may be correlated with infection status following exposure to MAP in vaccinated sheep. Therefore, we characterised the role of humoral immunity in sheep that were vaccinated and then became infected compared to vaccinated sheep that did not become infected. We assessed MAP-specific IgG1 and IgG levels and compared these with other aspects of B cell functionality, such as cell survival, differentiation, activation and receptor signalling, by gene expression in the gut tissues of these animals.

**Results**

**Animal trial**

Infection outcome in vaccinated and non-vaccinated sheep at the conclusion of the animal trial was determined by culture of live MAP from the intestine (Table 1). In the vaccinated animals exposed to MAP, two were found to be infected with live bacteria at 52 wpe and 18 had no culturable MAP at this time. In contrast, in the non-vaccinated sheep, 10 were found to be infected with MAP and 10 were uninfected at 52 wpe.

| Treatment | Infection status | n for ELISA | n for gene expression |
|-----------|-----------------|------------|----------------------|
| Vaccination | control | 5          | 3                    |
|            | infected | 2          | 2                    |
|            | uninfected | 18        | 4                    |
| Non-vaccination | control | 5          | 3                    |
|            | infected | 10         | 3                    |
|            | uninfected | 10        | 3                    |

Vaccinated and non-vaccinated infected sheep shed significantly more MAP in the faeces from 35 weeks post MAP exposure till the end of the trial, compared to both uninfected and control animals ($p < 0.05$) (Fig. 1).

**Serum antibody**

Vaccination significantly enhanced MAP-specific IgG1 levels in serum of sheep ($p < 0.001$) (Fig. 2a). In the vaccinated exposed animals, serum MAP-specific IgG1 was significantly higher in the cohort found to be uninfected at necropsy, compared to the infected animals. This polarised response was first evident prior to MAP exposure, as early as 1-month post vaccination ($p < 0.05$).

| Table 1 Numbers of animals included in IgG1 and tissue gene expression analyses |
|---------------------------------------------------------------|
| Treatment | Infection status | n for ELISA | n for gene expression |
|-----------|-----------------|------------|----------------------|
| Vaccination | control | 5          | 3                    |
|            | infected | 2          | 2                    |
|            | uninfected | 18        | 4                    |
| Non-vaccination | control | 5          | 3                    |
|            | infected | 10         | 3                    |
|            | uninfected | 10        | 3                    |
Serum MAP-specific IgG1 peaked in the vaccinated uninfected animals at 19 wpe and then tended to wane until the final sampling at 52 wpe. In contrast, the vaccinated infected animals had significantly lower levels of MAP-specific IgG1 ($p < 0.05$). The IgG1 response over time was also dissimilar to the vaccinated uninfected sheep, with the vaccinated infected animal’s MAP-specific IgG1 peaking at 11 wpe, decreased at 19 weeks and then increasing until the final sampling at 52 wpe.

Non-vaccinated animals had very low levels of MAP-specific IgG1 in serum compared to vaccinates. There were no significant differences between the non-vaccinated controls and the two non-vaccinated exposed groups (infected or uninfected) at any time point. However, in the non-vaccinated infected group, similar to the vaccinated infected sheep, MAP-specific IgG1 levels in serum tended to increase at the final sampling time point.

A similar pattern to the serum MAP-specific IgG1 response was also seen in the MAP-specific IgG data (Fig. 2b). Vaccinated animals had significantly greater MAP-specific IgG levels than non-vaccinates ($p < 0.001$). As with the MAP-specific IgG1, vaccinated uninfected sheep had higher MAP-specific IgG levels, which remained high throughout the animal trial. Interestingly, the vaccinated infected sheep had very low MAP-specific IgG levels that were not significantly different from the non-vaccinated sheep, until 11 wpe. At 19 wpe, MAP-specific IgG levels began to increase in these vaccinated infected animals, with a rapid increase from 27 to 35 wpe.

The polarised pre-exposure responses seen in the vaccinated infected and uninfected sheep was mimicked in the IgG1 response of vaccinated control animals. The vaccinated control sheep could be differentiated into high and low IgG1 responder groups at the pre-exposure time point (Fig. 3).
CI 0.021–0.605, \( p < 0.05 \)) and BAFF (fold change 0.06, CI 0.004–0.89, \( p < 0.05 \)) compared to non-vaccinated infected sheep. These same trends were seen in MIF expression, with an increase in expression in non-vaccinated infected animals and decreased expression in vaccinated controls and vaccinated uninfected sheep.

In research question 2, only the vaccinated animals were examined due to their dissimilarity in expression responses from non-vaccinated sheep. MAP exposure in vaccinated sheep was associated with upregulation of the majority of the genes of interest (Table 4). CD84 was the only differentially regulated gene, where vaccinated uninfected sheep had decreased expression compared to vaccinated infected sheep. The differences between vaccinated infected and uninfected sheep were further explored in research question 3. The majority of the genes examined were up-regulated in the vaccinated infected sheep compared to the vaccinated uninfected sheep. This increased expression was strongest for CD40LG, BAFF, MIF, CD84 and NFIL3 (Table 5). In contrast, both EGR1 and Lck tended to have reduced expression in the vaccinated infected animals compared to the vaccinated uninfected sheep.

In research question 4, the differences in gene expression between non-vaccinated and vaccinated sheep that were infected at necropsy was explored in more detail. The majority of the genes of interest were down regulated in the vaccinated infected animals compared to the non-vaccinated infected sheep (Q4 Table 2). This decreased expression was especially evident in BAFF, CD84 and Lck (Table 5).

**Discussion**

The exact role of B cells and antibodies in host immunity against intracellular pathogens has been a long-debated topic. We show here that B cell functionality is
important in vaccine-induced clearance of infection in animals exposed to MAP. A rapid and potent IgG1 antibody response was seen in all uninfected vaccinated sheep. Furthermore, at 12 months post exposure, these uninfected animals had a dampening of the humoral response at the site of paratuberculosis predilection, in contrast to the late switch to a humoral dominated response often associated with the transition to clinical paratuberculosis. On the other hand, vaccinated infected sheep had a slower IgG1 response to vaccination and had up regulated expression of genes related to the humoral immune response in the ileum at 12 months post exposure.

The serum MAP-specific IgG1 response in vaccinated uninfected sheep was elevated compared to the vaccinated controls and vaccinated infected sheep. This significant difference was already evident prior to MAP exposure suggesting a failure of the host to effectively mount an early IgG1 response post vaccination. The route of entry of MAP into the host macrophage can impact the ability of the host cell to kill it [31, 32]. Opsonised bacteria are more likely to interact with the Fc receptor (FcR) on the surface of monocytes and macrophages [33]. Phagocytosis of opsonised MAP via the FcR increases trafficking of intracellular bacteria to the lysosome and increases killing [33–36]. IgG1 has the highest affinity for the Fc receptor out of all IgG subclasses [37], and it stands to reason that animals that have a high IgG1 response to vaccination would be better equipped to eliminate MAP from the gut [19, 38]. The polarised IgG1 response in the vaccinated control animals, suggests that MAP specific IgG1 levels after vaccination, even in animals without MAP exposure, could be a useful predictor of vaccine efficacy.

The initial low level of serum MAP-specific IgG1 in vaccinated infected sheep, followed by a sharp increase, could signify the change from a Th1 to Th2 mediated response. The switch from a Th1 to Th2 immune response

**Table 2** Analysis matrix for sheep B cell-related gene expression in intestinal tissue for specific research questions

| Research question                                                                 | Baseline group                        | Comparison group (s)                  |
|----------------------------------------------------------------------------------|---------------------------------------|---------------------------------------|
| Q1. What gene expression changes are associated with disease outcome in non-vaccinated animals? Are these similar in vaccinated animals? | Non-vaccinated control                 | Non-vaccinated infected                |
|                                                                                  |                                       | Non-vaccinated uninfected             |
|                                                                                  |                                       | Vaccinated infected                   |
|                                                                                  |                                       | Vaccinated uninfected                 |
| Q2. What gene expression changes are associated with disease outcome in vaccinated animals | Vaccinated control                    | Vaccinated infected                   |
|                                                                                  |                                       | Vaccinated uninfected                 |
| Q3. What gene expression changes are associated with infection in vaccinated animals | Vaccinated uninfected                 | Vaccinated infected                   |
| Q4. What gene expression changes are associated with vaccination nonresponse in infected animals | Non-vaccinated infected               | Vaccinated infected                   |
in paratuberculosis has been associated with progression to clinical disease [5]. It is possible that the lack of an early antibody response in these animals aids early tissue invasion and leads to persistent infection, as animals with an inadequate IgG1 response appeared to be incapable of eliminating or controlling MAP. A similar late increase was also seen in the non-vaccinated infected animals, although to a much smaller magnitude. In stark contrast to these two groups, the vaccinated control and vaccinated uninfected animals appeared to have a gradual reduction in MAP-specific IgG1 in the serum towards the end of the trial. This reduction could signify a waning of the initial strong antibody response, either due to clearance of bacteria and decreased chronic antigenic stimulation, or the return to a more balanced immune state. The reduction of antibody levels, and presumably B cell response, could also lead to reductions in B cell related immunopathologies associated with an excessive response [39].

In the non-vaccinated sheep, there was no significant difference in levels of either IgG or IgG1 between the control, infected or uninfected animals at any sampling point. Low levels of MAP-specific IgG and IgG1 antibody are not unexpected in MAP exposed animals during the early stages of disease [4]. The differences seen between the vaccinated and non-vaccinated uninfected animals in terms of MAP-specific IgG1 could be the result of differences in the stimulus to induce protective immune responses. The immune response generated by a vaccine such as Gudair® is much stronger than that generated by natural exposure to MAP, due to continual antigen presentation via depot formation and the immune enhancing properties of the adjuvant [40].

The comparison of gene expression changes in the gut of sheep from multiple treatment groups created a dilemma as to what makes the best baseline group to determine fold change. As such, several different research questions were presented to explore the effects of

### Table 3: Gene expression changes (fold change) in the ileum of the different treatment groups compared to non-vaccinated control sheep

|                      | Non-vaccinated uninfected (n = 10) | Non-vaccinated infected (n = 10) | Vaccinated control (n = 5) | Vaccinated uninfected (n = 18) | Vaccinated infected (n = 2) |
|----------------------|-----------------------------------|---------------------------------|---------------------------|------------------------------|---------------------------|
| **Up regulated**     |                                   |                                 |                           |                              |                           |
| IgG1 (SP%)*          | 0.49                              | 10.75                           | 54.39                     | 91.09                        | 52.2                      |
| LYN                  | 2.1                               | 1.2                             | 1.4                       | 1.4                          |                           |
| GRB2                 | 1.8                               |                                 |                           |                              |                           |
| ERG1                 |                                   |                                 |                           |                              |                           |
| JUN                  |                                   |                                 |                           |                              |                           |
| NFIL3                |                                   |                                 |                           |                              |                           |
| LCK                  | 1.5                               | 3.2                             | 1.4                       | 2.8                          |                           |
| CD81                 | 1.5                               |                                 |                           |                              |                           |
| CD84                 |                                   |                                 |                           |                              |                           |
| CD40LG               | 2.5                               | 5                               |                           |                              |                           |
| BAFF                 | 1.5                               | 5†                              |                           |                              |                           |
| MIF                  | 1.1                               | 2.4                             |                           |                              |                           |
| **Down regulated**   |                                   |                                 |                           |                              |                           |
| LYN                  |                                   | −1.8                            |                           |                              |                           |
| GRB2                 |                                   | −1.2                            | −3                        | −1.1                         |                           |
| ERG1                 | −1.7                              | −3.8                            | −3.3                      | −1.4                         | −1.7                      |
| JUN                  | −1.4                              | −1.9                            | −1.9                      | −1.1                         |                           |
| NFIL3                | −1.1                              | −1.6                            |                           |                              |                           |
| LCK                  | −2.8                              | −1.2                            | −1.4                      | −1.1                         |                           |
| CD81                 | −3.6                              | −1.6                            | −1.6                      | −1.2                         |                           |
| CD84                 | −1.1                              | −2.1                            | −2.4*a                    | −1.1                         |                           |
| CD40LG               | −1.1                              | −1.1                            | −1.1                      |                              |                           |
| BAFF                 | −1.2                              | −1.2                            | −1.2                      |                              |                           |
| MIF                  | −2.9                              | −1.7                            |                           |                              |                           |

*IgG1 SP% of each group at the same timepoint as gene expression analysis was performed. Significant differences between groups are indicated by bolding (p < 0.05) with a significantly different to a and b significantly different to b.
vaccination, exposure to MAP and infection status on the expression of B cell related genes in the gut of ruminants.

Initially, to examine the impacts of both vaccination and infection outcome, the non-vaccinated control sheep were used as the baseline (Q1 Table 2). Vaccination alone decreased B cell-related gene expression and a similar pattern was found in vaccinated animals that resisted or recovered from infection (vaccinated uninfected). Previous work has suggested that early loss of B cell functionality could contribute to vaccine non-response [16], this lack of B cell activation in the current study could be due to samples being taken at a much later time point as well as differences in sample type (blood vs ileal tissue). There was an up-regulation of genes in ileal tissues in infected animals (both vaccinated and non-vaccinated) compared to healthy controls. Overall the results from this study suggests that a B cell response in the later stages of disease, at the site of infection, is not beneficial. Similarly, to the serum antibody results, a strong initial B cell mediated response could be beneficial, whilst a late response signifies progression to disease. The pattern of reduced expression in the vaccinated uninfected animals is likely to be due to clearance of MAP and subsequent return to an inactive or homeostatic immune state, which would be a response similar to the vaccinated unexposed animals where there is also no MAP to activate expression of B cell related genes.

In vaccinated animals, increased expression of CD40 ligand (CD40LG), JUN and B cell activating factor (BAFF) were related to infection status (Q2 Table 2). Engagement of CD40LG with the CD40 receptor on B cells is required for initiation and maintenance of the humoral immune response [41]. In the initial stages of humoral immunity after exposure, CD40/CD40LG signalling is required for the generation of high titres of class switched, high affinity antibodies [41]. During the progression of the immune response, signalling through these receptors encourages the development of memory B cells [39, 41]. The ligation of CD40 has been associated with production of AP-1 early response transcription factor, which is a heterodimer of cFOS and cJUN [42]. Overexpression of cJUN has been associated with prevention of apoptosis, highly increased proliferation and even immortalisation of B cells [43]. BAFF also plays a pivotal role in promoting the survival of plasmablasts, especially after CD40/CD40LG activation [39]. Proliferation and class switch triggered by CD40/CD40LG and then the prevention of apoptosis by BAFF and AP-1 would push the host’s immune response to one that is Th2 dominated [44]. The reduced expression of this gene in the vaccinated uninfected animals suggests that, at this timepoint, the humoral response in these animals is being downregulated or suppressed.

Interestingly, only Lck and EGR1 were down-regulated in the vaccinated infected sheep compared to the vaccinated uninfected animals, although this was not statistically significant. The expression of both of these genes influences B cell maturation, differentiation and antigen receptor signalling [45, 46]. Host tyrosine kinases, like Lck, are key host molecules utilised by intracellular pathogens to prevent killing [47]. In agreement with our work, the suppression of members of the Src family in chicken B cells renders them largely unresponsive to stimulation through the antigen receptor [45]. EGR1 expression is induced upon B cell antigen receptor signalling and accelerates B cell maturation [46]. The dysfunction of the B cell antigen receptor as a possible result of Lck gene down regulation could result in the reduced expression of EGR1. Therefore, it is possible that either upon vaccination or following MAP exposure B cell maturation and differentiation has been reduced.

**Table 4** Gene expression changes (fold change) in the ileum of the vaccinated infected and uninfected sheep compared to vaccinated control sheep

| Gene expression | Vaccinated uninfected (n=18) | Vaccinated infected (n=2) |
|-----------------|-----------------------------|--------------------------|
| Up regulated    |                             |                          |
| IgG1 (SP%)      | 91.09                       | 52.2                     |
| LYN             | 2.56                        | 2.86                     |
| GRB2            | 2.65                        | 4.33                     |
| ERG1            | 2.41                        | 1.89                     |
| JUN             | 1.75                        | 1.99                     |
| NFIL3           | 2.21                        | 4.47                     |
| LCK             | 2.72                        | 2.63                     |
| CD81            | 2.29                        | 3.14                     |
| CD84            |                             | 1.84                     |
| CD40LG          | 1.05                        | 5                        |
| BAFF            | 1.13                        | 2.52                     |
| MIF             | 1.67                        | 3.82                     |
| Down regulated  |                             |                          |
| LYN             |                             |                          |
| GRB2            |                             |                          |
| ERG1            |                             |                          |
| JUN             |                             |                          |
| NFIL3           |                             |                          |
| LCK             |                             |                          |
| CD81            |                             |                          |
| CD84            | −1.12                       |                          |
| CD40LG          |                             |                          |
| BAFF            |                             |                          |
| MIF             |                             |                          |

*G1 SP% of each group at the same timepoint as gene expression analysis was performed*
through the suppressed expression of these two genes, which is likely to diminish the memory response and could contribute to MAP persistence.

Although statistically significant differences were seen in this study, only a small number of the vaccinated exposed animals were infected at necropsy (n = 2). To validate the findings of this research, a larger number of vaccinated infected animals should be examined.

Conclusions

In conclusion, B cell responses were shown to be important to vaccine-mediated immune protection. A strong initial B cell response, characterised by MAP-specific IgG1 levels in serum, was seen in vaccinated sheep that cleared infection. Furthermore, this response appears to be toned down or tightly regulated towards the later stages of infection to prevent the dominance of the humoral response that likely marks the progression to clinical disease. The unique insight into the mechanisms behind vaccine immunity provided by this study will allow vaccine development to promote a strong initial humoral response and could possibly contribute to genetic selection for vaccine response in the future.

Methods

Animal trial

Fifty Merino sheep were purchased from a farm participating in the Australian Market Assurance scheme for Paratuberculosis. The wether lambs aged 4 months were sourced from a flock in Armidale, New South Wales (NSW), an area that has no prior history of Johne’s disease (JD). Absence of MAP infection was confirmed through extensive whole flock faecal tests and serum antibody ELISA [48]. On arrival at the university farm in Camden, NSW, sheep were randomly allocated into 4 treatment groups, Gudair™ vaccinated MAP unexposed (n = 5) and exposed (n = 20), Non-vaccinated MAP unexposed (n = 5) and exposed (n = 20). Sheep were managed under conventional Australian sheep farming conditions by grazing in open paddocks on unimproved pasture. During the trial all animals were examined daily and were weighed monthly. Faecal samples were collected from the rectum and blood samples via jugular venepuncture of all animals prior to inoculation and then every 3–4 months; collection order was non-purposive by selecting animals as they entered the handling yards. Blood and faecal samples were collected in sheep handling yards within the university farm land, and undertaken at a time of day when the weather was mild (between 15 and 25 °C) to reduce stress to the animals.

Vaccination with Gudair™ was performed in accordance with the manufacturer’s instructions and at 6 weeks post-vaccination a cohort were moved to quarantine paddocks and inoculated with MAP (Telford 9.2). The inoculation consisted of 3 oral doses (within a 4-week period) as described by Begg et al. [48] with a total of $9.25 \times 10^8$ viable MAP organisms. A non-vaccinated cohort was similarly exposed to MAP at the same time. Unexposed animals, vaccinated and non-vaccinated, were kept in separate paddocks to their exposed counterparts.

At the conclusion of the trial (52wpe), all animals were euthanised using an intravenous injection of barbiturate (Lethabarb™) at 0.5 ml/kg bodyweight. The disease status of all MAP exposed animals was then categorised based on liquid culture of MAP from gut tissues collected at necropsy, as described previously [49–51]. Animals with positive tissue cultures were classified as infected and those with negative results were classified as uninfected. A smaller subset of animals was used for gene expression examination in gut tissue (Table 1).

| Table 5 | Gene expression changes (fold change) in the ileum of sheep to answer specific research questions |
|---------|------------------------------------------------------------------------------------------------|
| Vaccinated infected compared to vaccinated uninfected (Q3) | Vaccinated infected compared to non-vaccinated infected (Q4) |
| Up regulated | | |
| LYN | 1.12 | 1.36 |
| GRB2 | 1.64 | 1.69 |
| ERG1 | 2.17 | |
| JUN | 1.14 | |
| NFIL3 | 2.03 | 1.28 |
| LCK | | |
| CD81 | 1.37 | |
| CD84 | 2.07 | |
| CD40LG | 5.37 | |
| BAFF | 2.22 | |
| MIF | 2.29 | |
| Down regulated | | |
| LYN | | |
| GRB2 | | |
| ERG1 | −1.27 | −1.36 |
| JUN | | −3.37 |
| NFIL3 | | −1.03 |
| LCK | −1.03 | −2.17 |
| CD81 | | −4.31 |
| CD84 | | −1.68 |
| CD40LG | | −7.52 |
| BAFF | | −1.82 |
| MIF | | |

Serum antibody levels

MAP specific IgG1 ELISA

ELISA plates (Nunc Maxisorb) were coated with 5 µg/ml MAP 316v, Protoplasmatic antigen A (PPA) or heat-killed
M. phlei. The ELISA plates were machine washed 5 times (Tecan, Austria) using wash buffer (phosphate buffered saline with 0.05% v/v Tween 20). Diluted serum (1/100) was added in duplicate to each antigen. Plates were incubated at 37 °C for 1 h, washed as described above and anti-IgG1 antibody (AbD Serotec, MCA 2440) was added. After a 1-h incubation at 37 °C, plates were machine-washed 5 times. Goat anti-mouse HRP (Dako P0447) was then added to each well and incubated at 37 °C for 30 min. Plates were washed as described earlier and TMB substrate (Pierce) added prior to incubating at room temperature in the dark for 20 min, the reaction was stopped with 2 M sulphuric acid and plates were read at 450 nm.

A single batch of positive and negative controls were included on each plate to standardise the ELISA. The positive serum controls were sourced from a sheep with high MAP specific serum antibody levels, as identified by the commercial IDEXX ELISA and the IgG1 ELISA. The negative control was serum from a sheep consistently test-negative for MAP-specific antibodies, as determined by the IDEXX ELISA and the IgG1 ELISA.

The MAP 316v antigen-specific IgG1 response was calculated using the following formula:

$$SP\% = \frac{OD_{\text{sample}} - OD_{\text{PPA negative control}}}{OD_{\text{PPA positive control}} - OD_{\text{PPA negative control}}} \times 100$$

*M. phlei* was included as a mycobacterial cross-reactivity control to ensure that responses seen in the IgG1 ELISA were MAP specific. PPA was included in the plate as a second MAP specific antigen and the ratio of PPA and 316 V response (1:0.8) was used to monitor positive control performance. Furthermore, the stronger PPA response was utilised to calculate SP%.

**MAP specific IgG ELISA**

The commercial IDEXX Pourquier ELISA (Idexx Laboratories, Australia) was used to determine MAP-specific serum IgG antibody levels. The ELISA was performed based on the manufacturer’s instructions.

**Faecal MAP detection**

A high throughput direct faecal PCR was used to quantify the amount of MAP shed in the faeces of all sheep, as previously described [52].

**Gene expression at the site of infection**

**Gene selection**

The genes to be examined were selected from a normalised and statistically analysed data set generated from previous microarray gene expression analysis (Affymetrix GeneChip) on sheep peripheral blood mononuclear cells (PBMC). This data set was generated from two sheep experimental infection trials that compared differential gene expression in animals vaccinated with Gudair™ and experimentally exposed to MAP compared to non-vaccinated MAP-exposed animals. Samples for gene expression analysis were taken at 13 wpe and 18 animals were used (9 vaccinated infected and 9 vaccinated uninfected). The raw data was normalised using the RNA (Robust Multichip Averaging) algorithm and significant differences were determined with ANOVA [53].

The data set was then examined using Ingenuity Pathway Analysis (IPA) software (version 01–01, Qiagen Bioinformatics). IPA was used to search for genes related to B cell functionality, survival, receptor signalling, migration and interaction with other immune cells within the data set. The overlay function was then used to examine the gene expression fold change in the microarray data set in relation to vaccination and disease outcome. Genes for qPCR analysis for the current study (Table 6) were then selected based on a fold change of greater than +/− 1.5 in PBMC.

**Tissue sections**

At the conclusion of the trial (52 wpe), all animals were necropsied. The gastrointestinal tract was removed and 3–4 cm sections of the mid to terminal ileum were excised. The sections were frozen at −80 °C prior to RNA extraction.

**RNA extraction and quality and quantity assessment**

RNA extraction was performed using RNAzol® RT (Merc) per the manufacturer’s instructions. The quality and quantity of purified RNA was assessed using a NanoDrop® ND-1000 UV-Vis Spectrophotometer (Thermo Scientific, Wilmington, DE), using the Nucleic Acid module. The absorbance at 260 nm was used to determine the RNA concentration where an A_{260} nm reading of 1.0 is equivalent to 40 μg/mL of RNA. Purity was characterised as a A_{260}/A_{280} ratio between 1.8 and 2 and a A_{260}/A_{230} ratio between 1.4 to 2.2. To remove contaminating genomic DNA and increase RNA purity, the samples were DNase treated and ethanol precipitated following extraction.

**cDNA generation**

cDNA was generated from RNA using the iScript™ cDNA Synthesis kit (Bio-Rad) per the manufacturer’s instructions, diluted 1/10 and stored at −80 °C until required.

**Primer selection and validation**

Forward and reverse primers (Table 6) were designed specifically for the gene regions of interest using online software Primer 3 [54] and checked for specificity using a BLAST search. As genes were selected based on expression levels in PBMC, gene expression in intestinal
changes were determined in comparison to pre-selected baseline group (Table 2) and the biological significance was set at a change of +/− 1.5 fold.

Statistical analysis
Restricted maximum likelihood (REML) in a linear mixed model (Genstat 16th edition; VSN International Ltd., Hemel Hempstead, United Kingdom) was used to analyse the MAP-specific IgG1, IgG serum ELISA results (S/P %) and MAP DNA quantity in the faeces. Sheep were grouped based on treatment coupled with infection status (vaccinated control, vaccinated infected, vaccinated uninfected, non-vaccinated uninfected, non-vaccinated control, non-vaccinated infected or non-vaccinated uninfected), which along with sampling time point was included as a fixed effect in the model. Animal ear tag number was included as a random effect.

When the REML analysis was significant, post-hoc tests to determine the significant differences between pairs of predicted means using the Fisher’s Least Significant Difference procedure were performed.

Abbreviations
BAFF: B cell activating factor; CD40L: CD40 ligand; CMI: Cell mediated immunity; ELISA: Enzyme linked immunosorbent assay; FcR: Fc receptor; IFN: Interferon gamma; IPA: Ingenuity pathway analysis; LcK: Lymphocyte specific protein kinase; MAP: Mycobacterium avium subspecies paratuberculosis; MIF: Macrophage migration inhibitory factor; PBMC: Peripheral blood mononuclear cell; PCR: Polymerase chain reaction;
PPA: Prototypic plasmacytoid antigen A; REML: Restricted maximum likelihood; wpe: Weeks post exposure

Acknowledgements
The authors would like to thank Anan Waldron, Ann-Michele Whittington, Nicole Carter and Rebecca Maurer for laboratory support. Additionally, we would like to thank Craig Kristo, James Dalton and Nobel Toribio for animal husbandry and sample collection assistance.

Authors’ contributions
Conceptualization, HP, DB, KP, RW, AP, and KdS; Formal Analysis, HP; Investigation, HP; Data Curation, AP; Methodology, DB, HP; Writing-Original Draft Preparation, HP; Writing-Review & Editing, HP, KP, KdS, DB, RW and AP; Supervision, KdS; Funding Acquisition, RW and HP. All authors have read and approved the publication of this manuscript.

Funding
This work was supported by Meat and Livestock Australia and by the Cattle Council of Australia, Sheep Meat Council of Australia, and Wool Producers Australia through Animal Health Australia (Grant no. PF5H0576) and an Australian Postgraduate Award and scholarship from Meat and Livestock Australia (HP). The funding body had no role in the design of the study, collection, analysis, and interpretation of data or in the writing of this manuscript.

Availability of data and materials
The datasets used and/or analysed during the current study available from the corresponding author on reasonable request.

Ethics approval and consent to participate
The experimental trial was approved by the University of Sydney Animal Ethics Committee (AEC) (ref no 6064) and conducted in compliance with the Animal Research Act 1985, Animal Research Regulation 2010 and the Australian code for the care and use of animals for scientific purposes 8th edition 2013 (the Code).

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Received: 17 January 2019 Accepted: 20 June 2019

Published online: 02 July 2019

References
1. Achkar JM, Prados-Rosales R. Updates on antibody functions in Mycobacterium tuberculosis infection and their relevance for developing a vaccine against tuberculosis. Curr Opin Immunol. 2018;53:30–7.
2. Ganustov V, Klinkenberg D, Bakker D, Koets AP. Evaluating contribution of the cellular and humoral immune responses to the control of shedding of Mycobacterium avium spp. paratuberculosis in cattle. Vet Res. 2015;46:62.
3. Stabel J. Host responses to Mycobacterium avium subsp. paratuberculosis: a complex arsenal. Anim Health Res Rev. 2006;7(1):61–70.
4. Sweeney RW. Pathogenesis of Paratuberculosis. Vet Clin N Am Food Anim Pract. 2011;27(3):537–46.
5. Stabel J. Transitions in immune responses to Mycobacterium paratuberculosis. Vet Microbiol. 2003;73(3-4):465-73.
6. Flynn JL, Chan J, Treibold KD, Dalton DK, Stewart TA, Bloom BR. An essential role for interferon γ in resistance to Mycobacterium tuberculosis infection. J Exp Med. 1993;178(6):2249–54.
7. de Silva K, Plain K, Purdie A, Begg D, Whittington R. Defining resilience to mycobacterial disease: characteristics of survivors of ovine paratuberculosis. Vet Immunol Immunopathol. 2018;195:56–64.
8. Waters WA, Bannantine JP, Miller JM, Palmer MV, Stabel JR, Jones DE, et al. Early induction of humoral and cellular immune responses during experimental Mycobacterium avium subsp. paratuberculosis infection of calves. Infect Immun. 2003;71(9):5130–8.
9. Begg DJ, de Silva K, Carter N, Plain KM, Purdie A, Whittington Rj. Does a Th1 over Th2 dominance really exist in the early stages of Mycobacterium avium subspecies paratuberculosis infections? Immunobiology. 2011;216(7):840–6.
10. Eppleston J, Redd acliff L, Windsor P, Links I, Whittington R. Preliminary observations on the prevalence of sheep shedding Mycobacterium avium subsp paratuberculosis after 3 years of a vaccination program for ovine Johne’s disease. Aust Vet J. 2005;83(10):637–8.
11. Windsor PA. Understanding the efficacy of vaccination in controlling ovine paratuberculosis. Small Rumin Res. 2013;110(2–3):161–4.
12. Kaufmann SHE. Future vaccination strategies against tuberculosis: thinking outside the box. Immunity. 2010;33(4):567–77.
13. Bannantine JP, Hines ME, Bermudez LE, Talaat AM, Sreevatsan S, Stabel JR, et al. Rational framework for evaluating the next generation of vaccines against mycobacterium avium subspecies paratuberculosis. Front Cell Infect Microbiol. 2014;4:126.
14. Redd acliff L, Eppleston J, Windsor P, Whittington R, Jones S. Efficacy of a killed vaccine for the control of paratuberculosis in Australian sheep flocks. Vet Microbiol. 2006;115(1–3):77–90.
15. Kalls CH, Hesselink JW, Barkema HW, Collins MT. Use of long-term vaccination with a killed vaccine to prevent fecal shedding of Mycobacterium avium subsp paratuberculosis in dairy herds. Am J Vet Res. 2001;62(2):270–4.
16. de Silva K, Plain KM, Begg DJ, Purdie AC, Whittington RJ. CD4(+) T-cells, gammameta T-cells and B-cells are associated with lack of vaccine protection in Mycobacterium avium subspecies paratuberculosis infection. Vaccine. 2015;33(1):149–55.
17. Kozakiewicz L, Phua J, Flynn J, Chan J. The role of B cells and humoral immunity in mycobacterium tuberculosis infection. Adv Exp Med Biol. 2013;783:225–50.
18. Coussens PM. Model for immune responses to Mycobacterium avium subspecies paratuberculosis in cattle. Infect Immun. 2004;72(6):3089–96.
19. Achkar JM, Chan J, Casadevall A. B cells and antibodies in the defense against Mycobacterium tuberculosis infection. Immunol Rev. 2015;264(1):167–81.
20. Elkins KL, Bosio CM, Rhinehart-Jones TR. Importance of B cells, but not specific antibodies, in primary and secondary protective immunity to the intracellular bacterium Francisella tularensis live vaccine strain. Infect Immun. 1999;67(1):602–7.
21. Linton PJ, Harbertson J, Bradley LM. A critical role for B cells in the development of memory CD4 cells. J Immunol. 2000;165(10):5538–65.
22. Shen H, Whitmire JK, Fan X, Shedlock DJ, Kaech SM, Ahmed R. A specific role for B cells in the generation of CD8 T cell memory by recombinant listeria monocytogenes. J Immunol. 2003;170(3):1443–51.
23. Whitmire JK, Asano MS, Kaech SM, Sarkar S, Hannum LG, Shlomchik MI, et al. Requirement of B cells for generating CD4+ T cell memory. J Immunol. 2009;182(4):1868–76.
24. Begg DJ, Griffin JF. Vaccination of sheep against M. paratuberculosis: immune parameters and protective efficacy. Vaccine. 2005;23(42):4999–5008.
25. Cabral-Marques O, Ramos RN, Schimke LF, Khan TA, Amaral EP, Barbosa Bomfin CC, et al. Mycobacterium CD40 ligand deficiency dysregulates the macrophage transcriptome causing functional defects that are improved by exogenous IFN-γ. J Allergy Clin Immunol. 2016;139(3):900–912.
26. Roadgar M, Ross CT, Tarara R, Lowenstein L, Dandekar S, Smith DG. Gene expression and TB pathogenesis in rhesus macaques: TR4, CD40, CD40L, FAS (CD95), and TNF are host genetic markers in peripheral blood mononuclear cells that are associated with severity of TB lesions. Infect Genet Evol. 2015;36:396–409.
27. Liu K, Zhang Y, Hu S, Yu Y, Yang Q, Jin D, et al. Increased levels of BAFF and APRIL related to human active pulmonary tuberculosis. PLoS One. 2012;7(8):e38429.
28. Gore Y, Starlerts D, Maharashk N, Becker-Herman S, Kaneyuki U, Leng L, et al. Macrophage migration inhibitory factor induces B cell survival by APRIL related to human active pulmonary tuberculosis. J Biol Chem. 2008;283(5):2784–92.
29. Lutay N, Håkansson G, Alaridah N, Hallgren O, Westergren-Thorsson G, Godal Y. Mycobacteria bypass mucosal NF-κB signalling to induce an epithelial anti-inflammatory IL-22 and IL-10 response. PLoS One. 2014;9(1):e86466.
30. Ruku B, Hoshino Y, Belitskaya-Lévy I, Dawson R, Ross S, Gold JA, et al. Gene expression profiles of bronchoalveolar cells in pulmonary TB. Tuberculosis. 2008;88(1):39–51.
31. Souza CD, Evanson OA, Weiss DJ. Role of cell membrane receptors in the suppression of monocyte anti-microbial activity against Mycobacterium avium subsp. paratuberculosis. Microb Pathog. 2008;44(3):215–23.
32. Maglione PJ, Xu J, Casadevall A, Chan J. Fcy receptors regulate immune activation and susceptibility during Mycobacterium tuberculosis infection. J Immunol. 2008;180(5):3329–38.
33. Joller N, Weber SS, Müller AJ, Spörri R, Selchow P, Sander P, et al. Antibodies protect against intracellular bacteria by fc receptor-mediated lysosomal targeting. Proc Natl Acad Sci U S A. 2010;107(47):20441–6.
34. Jolly A, Colavecchia SB, Fernandez B, Fernandez E, Mundo SL. Antibodies induced by Lipooligosaccharide in bovines: characteristics and effects on the interaction between Mycobacterium Avium Subsp. Paratuberculosis and macrophages in vitro. Vet Med Int. 2011;2011:258479.
35. Jolly A, Lomparida S, Hajas SE, Mundo SL. Evidence of a pro-apoptotic effect of specific antibodies in a bovine macrophage model of infection with Mycobacterium Avium subsp. paratuberculosis. Vet Immunol Immunopathol. 2016;169:67–75.
36. Armstrong JA, D'Arcy Hart P. Phagosome lysosome interactions in cultured macrophages infected with virulent tubercle bacilli. Reversal of the usual nonfusion pattern and observations on bacterial survival. J Exp Med. 1975;142(1):1–16.
37. Collins AM, Jackson KJ. A temporal model of human Ige and IgG antibody function. Front Immunol. 2013;4:235.
38. Everman JJ, Bermudez LE. Antibodies against invasive phenotype-specific antigens increase Mycobacterium avium subspecies paratuberculosis translocation across a polarized epithelial cell model and enhance killing by bovine macrophages. Front Cell Infect Microbiol. 2015;5:58.
39. Avey DT, Kalled SL, Elyard JJ, Ambrose C, Bixler SA, Thien M, et al. BAFF selectively enhances the survival of plasmablasts generated from human memory B cells. J Clin Investig. 2003;112(2):286–97.
40. Awate S, Babiuk LA. Mut wiring. Mechanisms of action of adjuvants. Front Immunol. 2013;4:114.
41. Elgueta R, Benson MJ, De Vries VC, Wasiuk A, Guo Y, Noelle RJ. Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol Rev. 2009;225(1):152–72.
42. Francis DA, Karas IG, Ke X, Sen R, Rothstein TL. Induction of the transcription factors NF-κB, AP-1 and NF-AT during B cell stimulation through the CD40 receptor. Int Immunol. 1995;7(2):151–61.
43. Schreiber M, Kolbus A, Piu F, Szabowski A, Möhle-Steinlein U, Tian J, et al. Control of cell cycle progression by c-Jun is p53 dependent. Genes Dev. 1999;13(5):607–19.
44. Khalifeh MS, Stabel JR. Clinical disease upregulates expression of CD40 and CD40 ligand on peripheral blood mononuclear cells from cattle naturally infected with Mycobacterium avium subsp. paratuberculosis. Clin Vaccine Immunol. 2013;20(8):1274–82.
45. Sefton BM, Taddie JA. Role of tyrosine kinases in lymphocyte activation. Curr Opin Immunol. 1994;6(4):372–9.
46. Dinkel A, Warnatz K, Lederbatt B, Rolink A, Zipfel PF, Bürki K, et al. The transcription factor early growth response 1 (Egr-1) advances differentiation of pre-B and immature B cells. J Exp Med. 1998;188(12):2215–24.
47. Khalifa MS, Stabel JR. Clinical disease upregulates expression of CD40 and CD40 ligand on peripheral blood mononuclear cells from cattle naturally infected with Mycobacterium avium subsp. paratuberculosis. Clin Vaccine Immunol. 2013;20(8):1274–82.
48. Sefton BM, Taddie JA. Role of tyrosine kinases in lymphocyte activation. Curr Opin Immunol. 1994;6(4):372–9.
49. Dinkel A, Warnatz K, Lederbatt B, Rolink A, Zipfel PF, Bürki K, et al. The transcription factor early growth response 1 (Egr-1) advances differentiation of pre-B and immature B cells. J Exp Med. 1998;188(12):2215–24.
50. Khalifa MS, Stabel JR. Clinical disease upregulates expression of CD40 and CD40 ligand on peripheral blood mononuclear cells from cattle naturally infected with Mycobacterium avium subsp. paratuberculosis. Clin Vaccine Immunol. 2013;20(8):1274–82.